53
Patient Risk
Intermediate risk
CHA
2
DS
2
-VASc = 1 (men)
CHA
2
DS
2
-VASc = 2 (women)
High risk
CHA
2
DS
2
-VASc ≥2 (men)
CHA
2
DS
2
-VASc ≥3 (women)
Observe for high AHRE
burden or AF development
ARTESiA and NOAH will
provide some evidence
Anticoagulation indicated if
true AF documented by ECG
or if certainty of AF is high
"Innocent bystander"
B
?
C
A potential approach to patients with SCAF could consider both patient risk (as gauged by
the CHA
2
DS
2
-VASc score) and SCAF burden/duration. Circle A indicates patients at low
risk or with short and infrequent AHREs do not require anticoagulation; Circle B, patients
with intermediate risk and AHREs lasting >6 min to 24 h are an uncertain population but are
currently under study in 2 prospective randomized controlled trials; and Circle C, patients at
high risk with longer episodes could be considered reasonable candidates for anticoagulation,
although the precise threshold for SCAF duration remains uncertain. Reproduced with
permission from Noseworthy PA, et al. Copyright 2019 American Heart Association, Inc.
Modified from Freedman B et al. Copyright 2017 Springer Nature Limited.
